Cargando…
“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
BACKGROUND: Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of Chronic Myeloid Leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of Ind...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884017/ https://www.ncbi.nlm.nih.gov/pubmed/24393270 http://dx.doi.org/10.1186/1744-8603-10-3 |